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Abstract
Constitutive signaling of PI3K/Akt/mTOR plays a prominent role in malignant transformation and progression of B-cell non-
Hodgkin lymphomas (B-NHL) underscoring the need for PI3K targeted therapies. The pan-class I PI3-kinase inhibitor
BKM120 has shown preclinical activity in distinct malignancies and is currently tested in clinical trials. Intratumor
heterogeneity is an intrinsic property of cancers that contributes to drug resistance and tumor recurrence. Here, we
demonstrate that inhibition of PI3-kinases by BKM120 attenuates growth and survival of B-NHL cell lines by inducing
mitotic arrest with subsequent induction of intrinsic apoptosis. BKM120-mediated downregulation of Cyclin A and
activation of the CDK1/Cyclin B1 complex facilitates mitotic entry. In addition, concomitant BKM120-mediated
upregulation of Cyclin B1 expression attenuates completion of mitosis, which results in mitotic catastrophe and apoptotic
cell death. In Bax and Bak deficient B-NHL, which are resistant to BKM120-induced apoptosis, BKM120-induced mitotic
catastrophe results in polyploidy. Upon re-expression of wt p53 in these p53 mutated cells, BKM120-induced polyploidy is
strongly reduced demonstrating that the genetic status of the cells determines the outcome of a BKM120-mediated
pathway inhibition. Mitotic catastrophe and unfavorable induction of polyploidy can be prevented in this setting by
additional inhibition of MEK1/2 signaling. Combining MEK1/2 inhibitors with BKM120 enhances the anti-tumor effects of
BKM120, prevents prognostic unfavorable polyploidy and might be a potential strategy for the treatment of B-NHL.
Introduction
In B-cell non-Hodgkin lymphoma (B-NHL), gene
amplification of the PI3K (phosphatidylinositol-4,5-
bisphosphate 3-kinase) subunit p110α, or loss of its
antagonist PTEN (phosphatase and tensin homolog)
facilitate constitutive activation of PI3K and its down-
stream targets Akt/PKB and mammalian target of rapa-
mycin (mTOR), which is associated with malignant
transformation, tumor progression, and resistance against
chemo- and radiotherapy1. Transient activation of the
PI3K/Akt/mTOR pathway mediates G1/S transition by
controlling cell cycle regulators such as Cyclin D1. Con-
stitutive Akt/PKB signaling, however, can bypass not only
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DNA damage-induced G1/S arrest but also G2/M
checkpoint arrest2,3. Data from non-small cell lung car-
cinoma cell lines implicated that PI3K is essential for
mitosis, as treatment with PI3K inhibitors induces death
by mitotic arrest, also termed mitotic catastrophe4.
Apoptosis can be abrogated by Akt/mTOR-mediated
activation of anti-apoptotic members like Bcl-2 and Mcl-1
or inactivation of pro-apoptotic factors, such as caspase-9
and Bad5–8. Therefore, constitutive activation of the PI3K/
Akt/mTOR pathway impedes tumor cell killing and
Fig. 1 BKM120 affects Akt/mTOR signaling and has anti-proliferative as well as pro-apoptotic activity. a Phosphorylation of distinct PI3K
downstream targets in MINO, GRANTA-519, and SU-DHL-10 after incubation with BKM120 at the indicated concentrations for 6 h. b Panel of non-
Hodgkin lymphoma cell lines incubated with increasing concentrations of BKM120 for 72 h. Metabolic activity was assessed using the XTT assay
(upper panel). Cell death induction was assessed using PI uptake (middle panel). Time dependent proliferation was assessed by counting the cell
number of NHL cells treated with 2 µM and exclusion of dead cells by trypan blue staining (lower panel). All panels show mean and SD of three
independent experiments. c Annexin-V-FITC/PI assay of the B-NHL cell line panel after incubation with 2 µM BKM120 for 72 h. Percentages refer to
cells positive for both, PI and Annexin-V-FITC staining (upper right quadrant) and cells positive only for Annexin-V-FITC staining (lower right
quadrant), respectively. Results are representative for three independent experiments
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constitutes therapy resistance. In addition, involvement of
PI3K/Akt/mTOR signaling in the regulation of alternative
cell death mechanisms, such as autophagy, mitotic cata-
strophe, and necroptosis has been shown4,9.
The pivotal role of PI3K/Akt/mTOR signaling in pro-
liferation and survival of tumor cells nominates this
pathway as a target for therapeutic intervention. Temsir-
olimus, a derivative of the mTORC1 inhibitor rapamycin,
gained approval for the treatment of mantle cell lym-
phoma (MCL)10. However, the effects of temsirolimus
monotherapy in B-NHL are limited10,11. Possible reasons
are feedback signaling via mTORC2 or S6K/IRS-1, both
restoring Akt/PKB activity12–14. This suggests that
blockade of upstream PI3K signaling may circumvent
feedback signaling and could be far more effective. NVP-
BKM120 (BKM120), a novel pan-class I PI3K inhibitor, is
currently tested in different clinical trials15,16. Here we
demonstrate that BKM120 induces mitotic catastrophe in
B-NHL cell lines, leading to apoptosis or polyploidy
depending on the availability of functional Bax, Bak and
p53. Mitotic catastrophe is triggered by BKM120-
dependent activation of the CDK1/Cyclin B1 complex
and concomitant upregulation of Cyclin B1 accompanied
by a strong mitotic arrest. Concomitant inhibition of
MEK1/2 signaling blocks Cyclin B upregulation, enhances
favorable apoptosis in sensitive and blocks unfavorable
polyploidy in resistant cell lines.
Results
BKM120 inhibits PI3K/Akt/mTOR signaling and has anti-
proliferative activity in B-NHL cells
BKM120 abrogates PI3K signaling in three widely used
B-NHL lines as indicated by decreases phosphorylation of
downstream targets (Fig. 1a). BKM120 reduced S6K
threonine 389 (T389) phosphorylation at concentrations
of 1.5 µM in MINO and 1 µM in GRANTA-519 and SU-
DHL-10 cells. Similarly, T37/46 phosphorylation of
4EBP1 was reduced in response to treatment with
BKM120 at concentrations of 1.5 µM. Next, we examined
the impact of BKM120 on the proliferation of B-NHL,
including cell lines from mantle cell lymphoma (MINO,
JEKO-1, REC-1, MAVER-1, and GRANTA-519), Burkitt
lymphoma (CA-46, DG-75) and diffuse large B-cell lym-
phoma (SU-DHL-10). Treatment abrogated the metabolic
activity of all cell lines (Fig. 1b, upper panel), but induced
cell death only in MINO, JEKO-1, REC-1, MAVER-1, and
GRANTA-519 cells (sensitive subgroup) as demonstrated
by propidium iodide (PI) uptake (Fig. 1b, middle panel). In
contrast, BKM120 did not induce cell death in CA-46,
SU-DHL-10, and DG-75 cells (resistant subgroup). We
Fig. 2 BKM120 kills cells via the intrinsic apoptosis pathway. a Annexin-V-FITC/PI assay in MINO and JEKO-1 cells in response to 2 µM BKM120 for
48 h and concomitant blockage of caspases with 10 µM QV-D-OPh. Percentages refer to cells positive for both, PI and Annexin-V-FITC staining (upper
right quadrant) and cells positive only for Annexin-V-FITC staining (lower right quadrant), respectively. Results are representative for three
independent experiments. b Measurement of the protein levels of Bax and Bak and cleavage/activation of caspase-9 in MINO cells in response to 1
µM and 1.5 µM of BKM120 incubated for 24 h. c Relative mRNA expression levels of Bcl-2 family members after incubation of JEKO-1 cells with 1.5 µM
of BKM120 for the indicated time points [h]. Mean ± SD of three independent experiments
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also determined total cell numbers upon BKM120 treat-
ment in the resistant cell lines compared to sensitive
MINO control-cultures. Over time, cell numbers
decreased in case of MINO and hardly increased in
resistant cell lines (Fig. 1b, lower panel), demonstrating
that BKM120 has an anti-proliferative effect on B-NHL
cells.
BKM120 induces intrinsic apoptosis in sensitive B-NHL cell
lines
To test whether BKM120 induces apoptotic cell death
in sensitive B-NHL cell lines, BKM120 treated cells were
stained for phosphatidylserine exposure by Annexin-V-
FITC binding and counterstained with PI. Flow cytometry
analysis revealed, that incubation with 2 µM BKM120 for
72 h induced apoptosis in 53% of GRANTA-519, 89% of
REC-1, 76% of MINO, 65% of JEKO-1 and 54% of
MAVER-1 cells (Fig. 1c, bar graph in Supplement 1A).
Consistent with a BKM120-resistant phenotype, CA-46,
SU-DHL-10, and DG-75 cells were negative for Annexin-
V-FITC and Annexin-V-FITC/PI (Fig. 1c), even at con-
centrations of up to 100 µM (Supplement 1B, 1C). Time
escalation demonstrated most efficient induction of
apoptosis after 48 h in MINO or 72 h in GRANTA-519
(Supplement 2A). Pretreatment with the pan-caspase
inhibitor Q-VD-OPh reduced BKM120-induced phos-
phatidylserine externalization (Fig. 2a) and attenuated
DNA fragmentation as demonstrated in MINO and
JEKO-1 cells (Supplement 2B). BKM120 triggered a
conformational change of pro-apoptotic Bax and Bak
leading to the exposure of the respective N-terminus and
activation of the proteins (Supplement 2C), which was
accompanied by breakdown of the mitochondrial mem-
brane potential (Supplement 2D) and processing of the
initiator procaspase-9 (Fig. 2b), altogether indicating that
BKM120 induces the Bax/Bak-dependent intrinsic apop-
tosis pathway.
We next analyzed whether BKM120 controls the tran-
scription of BH3-only or anti-apoptotic Bcl-2 family
members, which are known to regulate Bax/Bak activa-
tion. When analyzing mRNA expression levels in JEKO-1
cells, we observed a pronounced increase in mRNA
expression of the BH3-only family members Puma and
Hrk within 6 h post BKM120 treatment (Fig. 2c). In
contrast, a weak and delayed upregulation of mRNA
expression was detected for Bik/Nbk and Bmf. Among the
anti-apoptotic Bcl-2 members, a transient increase of
Mcl-1 mRNA expression was observed within 6 h, while
Bcl-2 and Bcl-xL expression were not affected (Fig. 2c).
PI3K-inhibition by BKM120 induces mitotic catastrophe
Apoptosis is triggered in the context of attenuated
proliferation and cell cycle arrest. Therefore, we examined
the impact of BKM120 on cell cycle regulation. Treatment
with 1.5 µM BKM120 for 72 h induced G2/M cell cycle
arrest in all cell lines, irrespective of apoptotic sensitivity,
i.e., in 18% GRANTA-519, 26% REC-1, 32% MINO, 30%
JEKO-1, 30% MAVER-1, 36% CA-46, 36% SU-DHL-10,
and 36% DG-75 cells (Fig. 3a). G2/M arrest was initiated
as early as 6 h post BKM120 treatment and reached its
maximum by 48 h and 24 h, as demonstrated in MINO
and DG-75 cells, respectively (Supplement 3A).
Because the CDK1/Cyclin B complex regulates mitotic
entry, phosphorylation of CDK1 was assessed in MINO
and DG-75 cells. In both cell lines, CDK1 was phos-
phorylated at T161, which stabilizes binding of Cyclin B1
to CDK1. However, concurrent phosphorylation of Y15
(Fig. 3b), which prevents premature complex activation17,
indicates inactivation of the complex. In the presence of
BKM120, phosphorylation of CDK1 on T161 persisted,
while phosphorylation of Y15 was reduced, thus demon-
strating activation of CDK1/Cyclin B1 and implying
mitotic entry. Furthermore, treatment with BKM120
caused downregulation of Cyclin A and upregulation of
Cyclin B1 (Fig. 3b), indicating mitotic arrest because
degradation of Cyclin A is a prerequisite for metaphase to
anaphase transition and degradation of Cyclin B is
required for mitotic exit18. Thus, BKM120 facilitates
mitotic entry followed by mitotic arrest and mitotic
catastrophe.
To address if BKM120 triggers premature mitotic entry,
we synchronized DG-75 cells by a double-thymidine
block and compared the DNA content of control and
BKM120-treated cells upon release from the block
(Fig. 3c). 6 h after release, control and BKM120-treated
cells were in the S-phase (DNA content between 2n and
4n), 9 h after release in G2/M, showing synchronous
passing of S-phase, G2-phase and mitotic entry. 12 h after
release, control cells completed mitosis and re-entered the
cell cycle, as indicated by the increase of cells with 2n. In
contrast, BKM120 treated cells were arrested in mitosis,
as demonstrated by cells with 4n. This finding was con-
firmed by immunoblot analysis of the mitotic marker
phospho-histone H3 (pHH3) Ser10 (Fig. 3d). Expression
of pHH3-Ser10 9 h after release was comparable between
control and BKM120-treated cells, indicating no time
differences in mitotic entry. A more pronounced pHH3
expression 12 h after release reflects the mitotic arrest of
BKM120-treated cells. To examine whether BKM120
induces replication stress and whether DG-75 cells enter
mitosis in the presence of DNA damage, expression of
γH2AX was analyzed. Immunoblotting revealed no
abundant γH2AX expression in BKM120-treated DG-75
cells entering mitosis. Twelve hours after release, γH2AX
is slightly increased in BKM-treated cells, which might
indicate mitotic stress and damage associated with mitosis
failure. Overall we show that, despite downregulation of
Cyclin A and upregulation of Cyclin B1, BKM120 does
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Fig. 3 BKM120 induces mitotic arrest. a Cell cycle distribution of NHL cell lines incubated with the indicated concentrations of BKM120 for 72 h.
Quantification with ModFit LT. Tetraploid cells are designated as 4n and hyperdiploid cells as 8n. Normal DNA content of 2n or 4n is colored in red, cells
with hyperdiploid DNA content are yellow. Cells in S-phase are labeled with blue grid. Sub G1 cells are gray. Data are representative for three independent
experiments. b Phosphorylation and expression status of cell cycle proteins in the two cell lines MINO and DG-75 after incubation with the indicated
concentrations of BKM120 for 24 h. c DG-75 cells were synchronized by a double-thymidine block. Upon release from the thymidine block, DNA content of
synchronized control cells and cells treated with 1.5 µM BKM120 was analyzed by flow cytometry. Representative histograms are shown. d Expression of the
mitotic marker phospho-histone H3 (pHH3) Ser10 in synchronized DG-75 control and BKM120 treated cells was analyzed by Western blot analysis
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not induce replication stress or premature, uncoordinated
mitotic entry.
Apoptosis resistance and p53 deficiency trigger BKM120-
dependent polyploidy
In apoptosis-resistant B-NHL cells, PI3K blockade by 2
µM BKM120-induced polyploidy (8n cells) in 5% of CA-
46, 36% of SU-DHL-10 and 59% of DG-75 cells (Fig. 3a).
Prolonged treatment with BKM120 for up to 216 h led to
the formation of 16n cells in DG-75 (Fig. 4a). In addition,
a massive increase of cell size was observed in CA-46 and
DG-75 cells (Fig. 4b). This underscores that duplication of
the DNA was triggered by multiple replications without
mitotic cell division. To analyze if PI3K inhibitors other
than BKM120 induce cell death or polyploidy in resistant
B-NHL cells, we treated DG-75 cells with LY294002,
BEZ235, and Wortmannin. In contrast to MINO cells
which were used as controls, none of the drugs-induced
cell death in DG-75 cells (Supplement 3B). Remarkably,
only BKM120-induced polyploidy in DG-75 cells
(Supplement 3C).
Because our results suggested a link between BKM120-
mediated polyploidy and apoptotic resistance, we next
examined the expression levels of apoptotic regulators
(Fig. 5a). Western blot analysis showed that procaspase-8
was variably expressed in all sensitive cell lines, barely
detectable in the resistant cell lines SU-DHL-10 and DG-
75, but clearly expressed in resistant CA-46 cells.
Caspase-9 was expressed at comparable levels in all
resistant and most sensitive cell lines, but slightly reduced
in sensitive GRANTA-519 cells. Caspase-3 was slightly
reduced in the resistant cell lines SU-DHL-10 and DG-75,
but clearly expressed in the resistant cell line CA-46.
Altogether there is no correlation between expression
levels of caspases and sensitivity of cell lines.
Similarly no correlation was observed for the protein
levels of the anti-apoptotic Bcl-2 family members Bcl-2
and Bcl-xL and BKM120 resistance (Fig. 5a). To analyze if
the high expression of Mcl-1 observed in all resistant cell
lines is involved in resistance, we treated cells with
Sabutoclax, a Bcl-2/Bcl-xL inhibitor and potent Mcl-1
antagonist. Sabutoclax-induced apoptosis in MINO and
MAVER-1 cells and sensitized MAVER-1 for BKM120-
induced apoptosis (Supplement 4). In contrast, CA-46,
SU-DHL-10, and DG-75 cells were resistant to
Sabutoclax-induced apoptosis and inhibition of Mcl-1
failed to sensitize these cells for BKM120 induced cell
death indicating that Mcl-1 is not linked to BKM120
resistance.
Interestingly, Bax and Bak were clearly expressed in all
sensitive cell lines, whereas no Bax or Bak expression was
observed in the three resistant cell lines (Fig. 5a). To
analyze the role of Bax/Bak, we examined BKM120-
induced apoptosis in the HCT116 cell line model system,
where a Bax/Bak double knockout (Bax/Bak DKO) is
available19,20. In HCT116 wild-type (WT) cells, BKM120-
induced apoptosis in a dose-dependent manner (Fig. 5b,
upper panel) with only a slight increase of polyploid cells
at high-BKM120 concentrations (Fig. 5c). In HCT116
Bax/Bak DKO cells, BKM120-mediated apoptosis was
attenuated (Fig. 5b, upper panel) but polyploidy was not
increased compared to HCT116 WT cells. Thus, Bax/Bak
deficiency incurs apoptotic resistance but is not sufficient
to facilitate BKM120-mediated polyploidy.
Because all three B-NHL cell lines that developed
BKM120-mediated polyploidy carry p53 mutations21
(http://p53.iarc.fr/CellLines.aspx), we next assessed the
impact of additional siRNA-mediated p53 downregulation
(Supplement 5A) on BKM120-induced polyploidy. Nei-
ther in HCT116 WT nor in Bax/Bak DKO cells down-
regulation of p53 did influence BKM120-mediated
apoptosis (Fig. 5b, lower panel). However, in contrast to
HCT116 WT cells, p53 downregulation lead to the
induction of BKM-mediated polyploidy in HCT116 Bax/
Bak DKO cells (Fig. 5c). This demonstrates that BKM120-
dependent polyploidy requires the concomitant loss of
Bax/Bak and p53. HCT116 cells harbors an activating
KRAS mutation, which increases signaling through the
MEK/ERK pathway indicated by constitutive MEK1/2
phosphorylation (Supplement 5B). Upon BKM120
Fig. 4 BKM120 induces polyploidy in apoptosis-resistant cells. Prolonged treatment of CA-46 and DG-75 with 1.5 µM of BKM120. Data are
representative for three independent experiments. a DNA content and cell cycle distribution. b Light microscopy image after 216 h
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treatment MEK1/2 phosphorylation is, like Cyclin B1
expression, not further increased, and CDK1 Y15 phos-
phorylation is reduced. However, upon BKM120 treat-
ment HCT116 cells essentially reflect BKM120-treated B-
NHL cells (activated MEK1/2, Cyclin B1 expression,
reduced CDK1 Y15 phosphorylation).
To verify the results in B-NHL cell lines, p53 was re-
expressed in resistant DG-75 and SU-DHL-10 cells by
using pRTS1-p53, an episomal one-vector system22
allowing doxycycline-induced, conditional expression.
Dox-induced expression (on condition) of p53 was con-
firmed by Western blot analysis (Fig. 6a left panels).
Expression of p53 was accompanied by increased
expression of the cyclin-dependent kinase inhibitor
p21CIP1/WAF1, indicating functional p53 downstream sig-
naling. As shown before, BKM120 caused polyploidy in
resistant DG-75 and SU-DHL-10 cell lines (Fig. 6a right
panels). Upon re-expression of p53, however, polyploidy
was strongly reduced. In p53 re-expressing SU-DHL-10
cells CDK1 Y15 phosphorylation is still reduced upon
BKM120 treatment. However, p53 re-expression almost
completely suppressed expression of Cyclin B1 and
inhibited BKM120-mediated activation of MEK1/2
(Fig. 6b), indicating that besides upregulation of p21,
reduced MEK1/2 activation and suppression of Cyclin B1
contribute to the inhibition of BKM-induced polyploidy
by p53.
Polyploidy is MEK1/2 dependent
To analyze the impact of BKM120 on MAPK signaling,
we explored the activation of MEK1/2 in MINO and DG-
75 cells. BKM120 treatment induced phosphorylation of
MEK1/2 at S217/221 (Fig. 7a). To examine whether
MAPK signaling is important for BKM120-induced
CDK1/Cyclin B1 activation and mitotic catastrophe,
MEK1/2 activity was abrogated by U0126. In both cell
lines, pretreatment with U0126 attenuated phosphoryla-
tion of CDK1 at T161 and Y15 (Fig. 7b). Additional
administration of BKM120 did not affect T161 or Y15
phosphorylation. Hence, U0126 abrogated BKM120-
Fig. 5 Concomitant Bax, Bax, and p53 deficiency determines polyploidy. a Basal protein expression levels of apoptotic regulators in a panel of
NHL cell lines. b Annexin-V-FITC/PI assay of HCT116 WT or HCT116 Bax−/−/Bak−/− cells incubated with increasing concentrations of BKM120 for 72 h
(upper panel). Annexin-V-FITC/PI assay of HCT116 WT or HCT116 Bax−/−/Bak−/− cells co-transfected with ctrl or p53 siRNA and incubated with 2.5 µM
BKM120 for 72 h (lower panel). Data show mean ± SD of three independent experiments. c Polyploidy assay of HCT116 WT or HCT116 Bax−/−/Bak−/−
cells co-transfected with ctrl or p53 siRNA and incubated with increasing concentrations of BKM120 for 72 h. Data show mean ± SD of three
independent experiments. *p < 0.05; **p < 0.005
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induced activation of CDK1/Cyclin B1 and mitotic cata-
strophe by regulating CDK1/Cyclin B1 assembling
upstream of BKM120. Furthermore, while BKM120
induces Cyclin B1 expression, concomitant treatment
with BKM120 and U0126 abolishes this effect, suggesting
that MEK1/2 is necessary for BKM120-mediated Cyclin
B1 upregulation (Fig. 7b).
To test whether concomitant inhibition of MEK1/2
affects BKM120-mediated apoptosis, MINO cells were
treated with U0126 and BKM120. Administration of
BKM120 alone induced apoptosis, while U0126 alone did
not (Supplement 5C). Interestingly, U0126 significantly
sensitized MINO cells for apoptosis-induced by BKM120.
When assessing the effect of combined treatment on
polyploidy in resistant DG-75 cells, treatment with U0126
alone did not affect ploidy of DG-75 cells, while co-
culture with U0126 and BKM120 reduced the amount of
polyploid cells (8n) from 36 to 6% (Fig. 7c). As pre-
treatment with U0126 clearly reduced BKM120-induced
polyploidy, MEK1/2 controls BKM120 triggered mitotic
arrest and polyploidy.
To examine why other inhibitors of PI3K fail to induce
polyploidy, we analyzed activation of MEK1/2 and Cyclin
B1 expression upon treatment of MINO and DG75 with
LY294002, BEZ235, and Wortmannin. In contrast to
BKM120, none of the inhibitors induced MEK1/2 acti-
vation or Cyclin B1 upregulation (Fig. 7d) and therefore
most likely fail to cause polyploidy.
BKM120-mediated events are reversible
To examine the sustainability of mitotic catastrophe and
polyploidy, transient BKM120 treatment was assessed in
CA-46 and DG-75 cells. Both cell lines were incubated
with BKM120 for 24 h or 72 h and re-cultured in medium
up to a total of 216 h (Fig. 8a). Control cells were incu-
bated with BKM120 for 216 h. In CA-46 cells, the highest
rate of BKM120-dependent mitotic cells (43%) was
observed after 72 h of incubation (Fig. 8a, CA-46, upper
panel). Removal of BKM120 after 24 h, attenuated the
amount of mitotic cells and prevented polyploidy (Fig. 8a,
CA-46, middle panel). When BKM120 was removed after
72 h, cells recovered from mitotic arrest and polyploidy
after 216 h (Fig. 8a, CA-46, lower panel). In DG-75 cells,
BKM120 induced mitotic arrest in 85% of the cells after
24 h and polyploidy in 49% of the cells after 144 h (Fig. 8a,
DG-75 upper panel). Removal of BKM120 after 24 h,
enabled DG-75 cells to recover from mitotic arrest and
polyploidy after an overall time of 216 h (Fig. 8a, DG-75
middle panel). When BKM120 was removed after 72 h,
mitotic cells decreased to 19% and polyploid cells
decreased to 29% after continued incubation for 216 h
(Fig. 8a, DG-75 lower panel). Removal of BKM120 after
short-term treatment for 24 h enabled both cell lines to
overcome growth inhibition and to restore proliferation
Fig. 6 Re-expression of wt p53 inhibits induction of polyploidy by
BKM120. DG-75 and SU-DHL-10 cells were transfected with pRTS1-p53,
an episomal vector system for regulated expression of wt p53. a
Western blot analysis confirmed overexpression of p53 under “on”
condition, which is accompanied by increased p21 expression (left).
FACS analyses of cellular DNA contend in resistant SU-DHL-10 and
DG-75 revealed induction of polyploidy (cells with 8n, top right
panels) by BMK120 treatment, which is strongly decreased by
concomitant re-expression of p53 (right panels). b Western blot
analysis of SU-DHL-10 cells revealed BKM120-induced increased Cyclin
B1 expression, MEK1/2 activation and decreased CDK1 Y15
phosphorylation in the absence of p53. In p53 re-expressing SU-DHL-
10 cells, Cyclin B1 expression is almost completely suppressed,
independently of BKM120 treatment. Furthermore activation of MEK1/
2 by BKM120 is strongly reduced upon p53 expression
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Fig. 7 BKM120-induced mitotic arrest and polyploidy requires MEK1/2. a Expression of phosphorylated MEK1/2 in MINO and DG-75 after
treatment with increasing concentrations of BKM120 for 3 h. b Expression of Cyclin B1 and phosphorylated CDK1 in MINO and DG-75 cells pretreated
with 50 µM U0126 for 4 h and subsequently incubated with 1 µM BKM120 for 24 h. c Measurement of cell cycle distribution and polyploidy of MINO
and DG-75 cells pretreated with 50 µM U0126 for 4 h and subsequently incubated with 1 µM BKM120 for 72 h. Quantification with ModFit LT. Data
shown are representative for two independent experiments. d WB analysis of MEK1/2 phosphorylation and Cyclin B1 expression in MINO and DG-75
cells upon treatment with 1.5 µM BKM120, 20 µM LY294002, 5 µM BEZ235, or 100 µM Wortmannin
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(Fig. 8b). In contrast, when BKM120 was removed after
72 h of incubation, only CA-46 cells were capable to
restart proliferation. Interestingly, continued treatment
with BKM120 for 216 h caused the formation of giant
cells, a hallmark of polyploidy, while strongly decreasing
the amount of normally sized cells in both cell lines
(Fig. 8c). Short-term incubation with BKM120 for 24 h,
but not 72 h, increased the amount of normally sized
cells. Giant cells, however, were still detectable.
BKM120 strongly induced phosphorylation of MEK1/2 at
S217/221, necessary for BKM120-induced polyploidy, in
both cell lines upon 24 h of treatment (Fig. 8d). Despite
the presence of BKM120, phosphorylation of MEK1/2
gradually decreased over time, which might explain
reduction of mitotic arrest and polyploidy upon pro-
longed BKM120 treatment.
Discussion
Pan-PI3K inhibitors impede proliferation and induce cell
death in various B-NHL cell lines and are currently tested
in clinical trials or already gained approval23–26. Here we
show that BKM120, a recently identified PI3K inhibitor,
effectively inhibited PI3K-pathway signaling, abrogated
proliferation, and induced G2/mitotic arrest in B-NHL cell
lines. The reported cell cycle effects of PI3K inhibition are
predominantly G1 arrest, but block of G2/M transition has
also been described2,27,28. BKM120 is known to induce G2/
M arrest in many cell lines29–32 but can also arrest cells in
the G1 phase33,34, indicating that downstream effects of
PI3K inhibition depend on the molecular background of
the cells. Furthermore, some non-specificity among the
inhibitors might be responsible for the different outcome,
e.g., LY294002 not only inhibits class I PI3Ks but also other
Fig. 8 BKM120-mediated processes are, in part, reversible. CA-46 or DG-75 cells temporarily treated with 1.5 µM BKM120. Reculture in media
after 24 h (BKM24) or 72 h (BKM72) or full length treatment for 216 h (BKM). a Cell cycle analysis was assessed by flow cytometry and analyzed with
ModFit LT. Data shown are representative for three independent experiments. b Proliferation was measured by counting the cell number and
counterstaining dead cells with trypan blue. Data shown are mean ± SD of three independent experiments. c Light microscopy image of cells
treated with BKM120 for 216 h. d WB analysis of phosphorylated MEK1/2 upon long-term treatment of CA-46 and DG-75 cells with 1.5 µM BKM120
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PI3K-related kinases like ATM, ATR35,36 and DNA-PK37.
In addition to G2/mitotic arrest and in contrast to other
PI3K inhibitors, BKM120 induces polyploidy in apoptosis-
resistant B-NHL cell lines. This effect clearly depends on
MEK1/2 activation by BKM120. Activated MEK1/2 might
induce G1/S transition with subsequent G2/mitotic arrest
due to BKM120-mediated PI3K inhibition.
BKM120 treatment caused activation of the mitotic
checkpoint regulator CDK1/Cyclin B1. Phosphorylation of
CDK1 at T161 stabilizes binding to Cyclin B17, while
concurrent phosphorylation at T14 and Y15 maintains
CDK1/Cyclin B inactive until conditions for mitosis are set.
In the B-NHL cell lines tested, BKM120 reduced inhibitory
Y15 but not activating T161 phosphorylation, thereby
empowering CDK1/Cyclin B and promoting mitosis.
Moreover, we observed that BKM120 induced the
downregulation of Cyclin A and upregulation of Cyclin B1.
We show here for the first time that BKM120-mediated
induction of Cyclin B1 depends on MEK1/2. However, the
exact mechanism of MEK1/2 activation and Cyclin B1
upregulation by BKM120 needs to be established.
Cyclin A degradation is required for metaphase–anaphase
transition and mitotic progression38,39, whereas degradation
of Cyclin B is required for completion of mitosis18. This
substantiates that BKM120 facilitates mitotic entry and
concomitantly prevents completion of mitosis resulting in
mitotic catastrophe. While a precise definition for mitotic
catastrophe is still missing, current knowledge indicates that
irregularities during mitosis, such as unrepaired DNA
damage or impaired spindle assembly, lead to mitotic cata-
strophe and facilitate distinct forms of programmed cell
death40. In B-NHL cells, BKM120-mediated mitotic cata-
strophe resulted in apoptosis via the Bax/Bak dependent
intrinsic pathway. Our quantitative RT-PCR analysis sug-
gests that transcriptional upregulation of the BH3-only
proteins Puma and Hrk participate in BKM120-mediated
apoptotic signaling. While Puma is a well-known target of
the PI3K/Akt pathway, there has been little evidence for
PI3K-dependent Hrk expression to date41,42. Despite strong
expression of Mcl-1, Sabutoclax did not sensitize resistant
cell lines for BKM120-induced apoptosis. This indicates that
Mcl-1 expression is not linked to BKM120 resistance but
might be related to functions of Mcl-1 not involved in the
regulation of apoptosis, e.g., regulation of mitochondrial
fusion, ATP production, regulation of ER Ca2+-transport
systems43–45 and inhibition of autophagy46,47.
Polyploidization, as shown here for BKM120-treated
resistant B-NHL cell lines, is a known feature of cells that
have evaded the apoptotic death program of mitotic cata-
strophe21,40,48,49. The inability of CA-46, SU-DHL-10. and
DG-75 cells to undergo apoptotic cell death results from the
loss of Bax and Bak expression, which also triggers poly-
ploidy in response to substances like paclitaxel or nocoda-
zole21,50,51. In addition to Bax and Bak, polyploidy induced
by BKM120 requires loss of p53, as demonstrated here in
HCT116 Bax/Bak DKO cells after downregulation of p53.
Furthermore, re-expression of p53 in B-NHL cells, which is
accompanied by upregulation of p21, reduced MEK1/2
activation and suppression of Cyclin B1, inhibited BKM120-
induced polyploidy. Interestingly, a combined inactivation of
p53 and Bax has been shown to result in a very poor disease
prognosis in B-CLL and solid tumors52,53. Furthermore, as
DNA ploidy appears to have a negative impact on prognosis
in general and on the tendency to metastasize in parti-
cular54,55, BKM120-mediated formation of polyploid cells
may have therapeutic relevance as loss of Bax and Bak is
observed in high-grade NHL and also contributes to NHL
resistance against rituximab and chemotherapy56,57.
The inverse relationship between apoptosis and poly-
ploidy reveals a decision point between mitosis progres-
sion, apoptosis and endoreplication21,58,59 and introduces
polyploidy as an alternative pathway when apoptosis and
cell cycle progression are obstructed21,49. This is, as shown
here for B-NHL cells, accompanied by massive increase in
cell size and the formation of giant cells, a prominent
morphological characteristic of cells undergoing mitotic
catastrophe. While underlying mechanisms are still unclear
several principles such as endoreplication or endocycling
are discussed, and endocycling has been specifically
observed in p53 deficient tumor cells50.
Our data demonstrated BKM120-mediated activation of
MEK1/2 and induction of Cyclin B1 expression. MEK1/2
inhibition abrogated BKM120-induced expression of
Cyclin B1 which can affect BKM120-mediated polyploidy
in two ways. Reduced Cyclin B levels might prevent
mitotic entry, thereby arresting cells at the G2 checkpoint,
which would inhibit mitotic catastrophe and subsequent
induction of polyploidy. However, degradation of Cyclin
B1 by anaphase-promoting complex/cyclosome is also
required for mitotic exit and completion of the cell cycle.
Reduced Cyclin B levels may therefore enable cells, which
have escaped mitotic arrest or are already in mitosis at
time of treatment, to successfully complete mitosis and
reenter the cell cycle thereby inhibiting induction of
polyploidy. In line with this, MEK1/2 activation was
reported to correlate with ploidy and endomitosis in
megakaryocytes60. In apoptosis sensitive cell lines, how-
ever, combination of BKM120 with U0126 synergistically
enhanced apoptosis, which is known from other PI3K and
MAPK inhibitors61. In contrast, BKM120-resistant cells
undergo cell death after prolonged treatment by a
caspase-independent mechanism (data not shown).
Interestingly, BKM120 can induce autophagy besides
apoptosis16,62. However, it has been shown that blocking
of MEK/ERK signaling attenuates BKM120-induced
autophagy63, making induction of autophagy after treat-
ment of cells with BKM120 and U0126 unlikely. Whether
cells alternatively die through a necroptotic form of cell
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death as shown before in other lymphoma therapy set-
tings64,65, requires further analysis.
In conclusion, pan PI3K inhibition with BKM120 has
anti-tumor potential for the treatment of B-NHL. Fur-
thermore, combination with MEK1/2 inhibitors appears
to enhance anti-tumor effects and to prevent prognostic
unfavorable polyploidy in vitro. Currently running trials in
advanced non-small Cell Lung Cancer combining the
MEK inhibitor MEK162 with the PI3Kα inhibitor BYL719
(NCT02276027) or the MEK inhibitor Selumetinib with




The NHL cell lines JEKO-1, GRANTA-519, REC-1,
MAVER-1, CA-46, DG-75, and SU-DHL-10 were pur-
chased from DSMZ (Deutsche Sammlung von Mikroor-
ganismen und Zellkulturen GmbH, Braunschweig,
Germany), while MINO was obtained from ATCC
(American Type Culture Collection, Manassas, VA, USA).
The colon carcinoma cell line HCT116 wild type
(HCT116 WT) was obtained from Dr. Bert Vogelstein
(Johns Hopkins Cancer Center, Baltimore, MD, USA) and
the HCT116 Bax/Bak double knockout (HCT116 Bax/Bak
DKO) were kindly provided by Dr. Richard J. Youle
(National Institutes of Health, Bethesda, MD, USA). All
lymphoma cell lines were cultured in RPMI supplemented
with 10% (GRANTA-519, REC-1, MINO) or 20% FCS
(JEKO-1, MAVER-1) and 100 U/ml penicillin plus 100 µg/
ml streptomycin. The HCT116 WT and HCT116 Bax/Bak
DKO were cultured in DMEM supplemented with 10%
FCS and 100 U/ml penicillin plus 100 µg/ml streptomycin.
Inhibitor treatment
The pan-class I PI3K inhibitor BKM120 was obtained
from Novartis (Novartis AG, Basel, Switzerland), solved in
DMSO and stored in 10mM stocks at −80 °C. For inhi-
bitor treatment, cell lines were seeded at a denstiy of 0.5 ×
105–1 × 105 cells in 24 wells (HCT116 cells at 1 × 105 in 6
wells) and incubated at 37 °C overnight. Diluted inhibitor
was added at the appropriate concentration and cells were
incubated for the indicated time. MEK1/2 activity was
blocked with the inhibitor U0126 from Calbiochem
(Merck KGaA, Darmstadt, Germany). Pan-caspase inhi-
bition was performed with QV-D-OPh from Calbiochem
(Merck KGaA, Darmstadt, Germany). Blockade of MEK1/
2 or caspases was induced by addition of the according
inhibitor 4 h prior to BKM120 treatment.
Metabolic activity assay
Proliferation was analyzed by the use of the cell prolifera-
tion kit II (XTT) from Roche (Basel, Switzerland) employing a
Tecan Spectra reader (SLT, Crailshaim, Germany).
Proliferation assay
Cells were treated with or without BKM120 and pro-
liferation was analyzed by counting viable cells by use of a
Neubauer chamber. Dead cells were identified by trypan
blue staining and were excluded from the analysis.
PI uptake
To determine overall cell death, cells with a disrupted
and permeable membrane were detected by addition of
propidium iodide (PI). Cells were collected after 72 h,
washed with 1× PBS and incubated in 40 µg/ml PI for 10
min. PI positive and thereby dead cells were measured by
flow cytometry.
Measurement of apoptotic cell death by flow cytometry
To define apoptotic cells, measurement of hypodiploid
cells was performed as previously described24. Alter-
natively, cell death was determined by staining cells with
Annexin-V-FITC and counterstaining with PI66. Early
apoptotic cells were identified as Annexin-V-FITC posi-
tive/PI negative whereas late apoptotic cells display a
permeabilized plasma memebrane and consequently are
double positive for Annexin-V binding and PI uptake.
Analyses were performed using a FACScan (Becton
Dickinson, Heidelberg, Germany) and CELLQuest analy-
sis software. Results are given in % of cells.
Bax/Bak activation
The activation of Bax and Bak was assessed by detecting
proteins that undergo conformational change as described
before24.
Immunoblotting
Protein expression and phosphorylation status was
detected by Western blot analysis. The antibodies α-
S6K T389, α-4EBP1 T37/46, α-Bax, α-caspase-8, α-Bcl-
2, α-Bcl-xL, α-CDK1 T161, α-CDK1 Y15, α-MEK1/2
S217/221 were purchased from Cell Signaling Tech-
nology, Inc. (Danvers, MA, USA). The antibodies α-
GAPDH, α-Mcl-1, α-Bak were obtained from Santa
Cruz Biotechnology, Inc. (Heidelberg, Germany). α-
caspase-9 and α-caspase-3 were purchased from R&D
Systems, Inc. (Minneapolis, MN, USA). The antibodies
α-p53, α-Cyclin B1, and α-Cyclin A were obtained from
BD Pharmingen (Heidelberg, Germany). The antibodies
α-pHH3 and α-γH2AX were purchased from Sigma-
Aldrich (Taufkirchen, Germany). Treated cells were
lysed in RIPA buffer67, proteins were isolated by cen-
trifugation and protein concentration was measured
using the BCA method. SDS-PAGE was performed as
described previously68. Transfer of proteins onto
nitrocellulose membrane was performed with Towbin
buffer and wet blot using the Trans-Blot® System from
Bio-Rad Laboratories (Hercules, CA, USA). For
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immunodetection, membranes were incubated with
primary antibody at 4 °C overnight. Radish peroxidase
labeled secondary antibody was added for 2 h at room
temperature and chemiluminescence signal was detec-
ted by the use of the ChemiDoc™ MP System (Bio-Rad
Laboratories, Hercules, CA, USA).
JC-1 assay
Loss of mitochondrial membrane potential was mea-
sured by JC-1 assay as described before24.
siRNA and transfection
Transfection of HCT116 WT and HCT116 Bax/Bak
DKO cells was performed using the Amaxa system (Lonza
Group AG, Basel, Switzerland). According to Lonza pro-
tocol, HCT116 cells were transfected using program D-
032 and solution V. To downregulate p53, siRNA, kindly
provided from Scheidereit AG (MDC, Berlin, Germany),
was used.
Quantitative RT-PCR
Quantitative PCR was performed as previously
described24.
Statistical analysis
Experiments have been performed at least as two
independent experiments and results were presented as
means ± standard deviation (SD). Where applicable, sta-
tistical significance of results was analyzed using Student’s
t-test.
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